Related Experiment Video
Updated: Jan 24, 2026
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
367
Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer
Emily K Kleczko1, Jeff W Kwak1, Erin L Schenk1
1Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Frontiers in Immunology
|May 29, 2019
Summary
Lung adenocarcinoma (LUAD) progression is complex, involving interactions between cancer cells and the tumor microenvironment. Understanding complement system roles is crucial for developing new LUAD immunotherapies.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Lung adenocarcinoma (LUAD) remains a leading cause of cancer death, with current treatments offering limited survival benefits.
- Despite advances in targeted therapies and immunotherapies, a significant gap exists in understanding cancer cell and tumor microenvironment (TME) interactions.
- The complement system, a key part of innate immunity, has a dual role in cancer, with recent evidence suggesting it can promote tumor progression.
Purpose of the Study:
- To review current knowledge of complement system activation and its effects on LUAD progression.
- To identify critical knowledge gaps hindering the clinical application of complement-targeted therapies for LUAD.
- To explore the potential of complement inhibitors as a therapeutic strategy for non-small cell lung cancer (NSCLC).
Main Methods:
- Review of existing literature on complement biology in cancer.
- Analysis of studies investigating complement activation pathways in LUAD.
- Examination of the role of anaphylatoxins (C3a, C5a) and the membrane attack complex (MAC) in LUAD and TME.
- Discussion of local vs. systemic complement production in tumors.
Main Results:
- Complement activation, initially thought to inhibit cancer, appears to promote LUAD progression via anaphylatoxins.
- Localized complement production by tumor and immune cells, not just systemic production, influences the TME.
- Immunoevasive pathways are engaged by complement activation, contributing to tumor growth.
- Numerous anti-complement drugs are in clinical development for NSCLC.
Conclusions:
- Complement system dysregulation plays a significant role in LUAD progression and immune evasion.
- Further research is needed to elucidate the precise mechanisms of complement action in LUAD.
- Targeting the complement system holds promise for novel LUAD treatment strategies, but requires a deeper understanding of its local and systemic roles.
Related Concept Videos
02:57Targeted Cancer Therapies
8.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.7K
01:27Complement System
9.9K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
9.9K
00:49Complementation Tests
6.1K
A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
6.1K
01:27C4 Pathway and CAM
48.9K
Most plants use the C3 pathway for carbon fixation. However, some plants, such as sugar cane, corn, and cacti that grow in hot conditions, use alternative pathways to fix carbon and conserve energy loss due to photorespiration. Photorespiration is the process that occurs when the oxygen concentration is high. Under such conditions, the rubisco enzyme in the Calvin cycle binds O2 instead of CO2, which halts photosynthesis and consumes energy.
C4 Pathway
The C4 pathway is used by plants such as...
C4 Pathway
The C4 pathway is used by plants such as...
48.9K
01:47Lung Capacity
56.2K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
01:13Therapeutic Index
6.7K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.7K